Literature DB >> 3953678

Osteogenesis imperfecta type III. Delineation of the phenotype with reference to genetic heterogeneity.

D O Sillence, K K Barlow, W G Cole, S Dietrich, A P Garber, D L Rimoin.   

Abstract

The existence of a rare form of osteogenesis imperfecta, OI type III, has been postulated. This is characterized by autosomal recessive inheritance with neonatal manifestations of bone fragility or deformability. It is usually nonlethal. Studies of some 345 pedigrees of OI in the last 8 years confirm that patients falling into this group are rare. They should be distinguished as a special group within the group of OI subjects with a progressively deforming OI phenotype delineated in previous publications [Sillence et al, 1979a, b]. The OI type III phenotype does not necessarily equate with progressively deforming OI, and probably only a proportion of cases with severe deformity and normal sclerae have OI type III. On the other hand, distinction between these patients and those with a milder form of perinatally lethal OI type II might be difficult. Whereas the natural history of skeletal deformity and fractures in patients with OI type III has certain similarities, variable severity between families indicates that OI type III is likely to be genetically heterogeneous.

Entities:  

Mesh:

Year:  1986        PMID: 3953678     DOI: 10.1002/ajmg.1320230309

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  26 in total

1.  Osteogenesis imperfecta due to recurrent point mutations at CpG dinucleotides in the COL1A1 gene of type I collagen.

Authors:  C J Pruchno; D H Cohn; G A Wallis; M C Willing; B J Starman; X M Zhang; P H Byers
Journal:  Hum Genet       Date:  1991-05       Impact factor: 4.132

Review 2.  Osteogenesis imperfecta: translation of mutation to phenotype.

Authors:  P H Byers; G A Wallis; M C Willing
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

3.  Arachnoid cyst and chronic subdural haematoma in a child with osteogenesis imperfecta type III resulting from the substitution of glycine 1006 by alanine in the pro alpha 2(I) chain of type I procollagen.

Authors:  W G Cole; T P Lam
Journal:  J Med Genet       Date:  1996-03       Impact factor: 6.318

4.  Disrupted growth plates and progressive deformities in osteogenesis imperfecta as a result of the substitution of glycine 585 by valine in the alpha 2 (I) chain of type I collagen.

Authors:  W G Cole; D Chan; C W Chow; J G Rogers; J F Bateman
Journal:  J Med Genet       Date:  1996-11       Impact factor: 6.318

Review 5.  Congenital and idiopathic scoliosis: clinical and genetic aspects.

Authors:  Philip F Giampietro; Robert D Blank; Cathleen L Raggio; Sajid Merchant; F Stig Jacobsen; Thomas Faciszewski; Sanjay K Shukla; Anne R Greenlee; Cory Reynolds; David B Schowalter
Journal:  Clin Med Res       Date:  2003-04

6.  SNTG1, the gene encoding gamma1-syntrophin: a candidate gene for idiopathic scoliosis.

Authors:  Stavros Bashiardes; Rose Veile; Missy Allen; Carol A Wise; Mathew Dobbs; Jose A Morcuende; Lazlos Szappanos; John A Herring; Anne M Bowcock; Michael Lovett
Journal:  Hum Genet       Date:  2004-04-16       Impact factor: 4.132

7.  Recurrence risks and prognosis in severe sporadic osteogenesis imperfecta.

Authors:  E M Thompson; I D Young; C M Hall; M E Pembrey
Journal:  J Med Genet       Date:  1987-07       Impact factor: 6.318

8.  Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible.

Authors:  G A Wallis; B Sykes; P H Byers; C G Mathew; D Viljoen; P Beighton
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

9.  Radiological "metamorphosis" in a patient with severe congenital osteogenesis imperfecta.

Authors:  F Pendola; C Borrone; M Filocamo; M Lituania; B Steinmann; A Superti-Furga
Journal:  Eur J Pediatr       Date:  1990-03       Impact factor: 3.183

10.  Osteogenesis imperfecta: a clinical study of the first ten years of life.

Authors:  U Vetter; B Pontz; E Zauner; R E Brenner; J Spranger
Journal:  Calcif Tissue Int       Date:  1992-01       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.